Stem Cell Therapy in Japan: A Guide for International Patients

International patients can access autologous stem cell therapy in Japan, though every prospective patient goes through a physician-led eligibility review before any treatment plan or travel itinerary is confirmed.

What autologous stem cell therapy involves

Autologous stem cell therapy uses a small volume of your own adipose (fat) tissue as the source material. Cells are isolated, expanded, and purified at a cell-processing facility under clean-room conditions, then reintroduced to your body by intravenous infusion. Because the cells originate from you and are returned to you, the treatment is intended to support your body's own regenerative and circulatory capacity, not to introduce foreign biological material.

Regenerative medicine in Japan — including autologous adipose-derived stem cell infusion — is provided within Japan's Act on the Safety of Regenerative Medicine, which requires review by a certified regenerative medicine committee before treatment begins. StemCellor organizes information and appointment coordination; the receiving licensed physician or medical institution confirms which regulatory category applies and whether treatment can be appropriately offered for your case. Our Safety & Regulation overview covers this framework in full.

Who typically considers this treatment

Patients typically research autologous stem cell therapy for a few recurring reasons: general fatigue or a decline in day-to-day resilience, joint or tissue concerns they'd like to address without surgery, circulatory and metabolic health as part of a broader longevity plan, or support during a major hormonal transition such as perimenopause. None of these are diagnoses this treatment is intended to cure — your physician discusses what's realistically achievable for your specific case during consultation, not a fixed outcome. Full detail on the treatment itself is on our Stem Cell Therapy page.

How the process works, from consultation to follow-up

The process starts with a consultation and infectious-disease blood screening, followed by a brief outpatient tissue-collection procedure, several weeks of cell culture and purification, and finally the infusion itself with a follow-up review. Because culturing takes several weeks, this treatment is typically planned across two visits to Tokyo rather than a single trip — most patients return home between the collection and infusion steps. Our International Patient Guide walks through this timeline in more detail, along with what to prepare before you travel.

What determines whether you're a candidate

Eligibility is confirmed individually by a licensed physician, not guaranteed by researching the treatment or by any figure published on this site. Patients with active cancer or certain prior malignancies, an unresolved infectious-disease screening result, significant uncontrolled medical conditions, or who are pregnant or breastfeeding are generally not suitable candidates, and some patients are advised to delay treatment rather than proceed immediately. This is a normal, expected outcome of an honest review, not a rare exception. Published pricing for every step mentioned above is on our Pricing page.

Frequently asked questions

Is stem cell therapy legal in Japan?

Yes. It's governed by Japan's Act on the Safety of Regenerative Medicine, which classifies treatments by risk level and requires provider review by a certified regenerative medicine committee before treatment can begin. See our Safety & Regulation overview for the full framework.

Can I book my flights as soon as I decide to look into treatment?

We recommend against it. Travel should not be arranged until your physician eligibility review is complete, so your trip isn't booked around a treatment plan that hasn't been confirmed yet.

Will I know exactly what this will cost before I travel?

Standard pricing is public and listed on our Pricing page, but your final treatment plan and its exact costs are confirmed only after your physician's assessment, since candidacy and any additional items vary by individual.

What if I'm not a suitable candidate?

Your physician will tell you directly and explain why — whether that means treatment isn't appropriate for your case or should be delayed until a specific condition is addressed.

Where can I get more specific answers to my own questions?

Our FAQ page covers eligibility, safety, pricing, travel, and what we can and cannot promise across all three of our treatment areas.

References

Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J, Stewart DJ; Canadian Critical Care Trials Group. "Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials." PLoS ONE. 2012;7(10):e47559. DOI: 10.1371/journal.pone.0047559